Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#2819 Occurrence of Pancreatic Exocrine Insufficiency in Patients with Advanced Neuroendocrine Tumours Treated with Somatostatin Analogue

Introduction: Neuroendocrine neoplasia (NENs) are heterogeneous tumours caracterized by a relatively indolent rate of growth. Usually, in G1 and G2 GEP-NENs, first-line therapy is SSAs, considering their efficacy, good safety profile, and antiproliferative effects. SSA treatment inhibits the production and excretion of pancreatic enzymes and PEI is known to be an adverse effect of SSA treatment.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Rinzivillo M

Authors: De Felice I, Rinzivillo M, Pratesi M, Magi L, Annibale B,

Keywords: Pancreatic Exocrine Insufficiency,

#2808 Clinical Features and Quality of Life in Patients with Gastroenteropancreatic Neuroendocrine Tumors from Chile

Introduction: Clinical features of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) and their repercussions on health-related quality of life (HRQoL) have not been widely studied in Hispanic populations.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Carrillo D

Authors: Carrillo D, Munoz-Anguita G, Madison A, Retamal I, Pinto M,

Keywords: Neuroendocrine, Carcinoid, Health-related quality of life.,

#2803 Chromogranin A as a Tumoral Marker for Neuroendocrine Tumors in Chilean Patients: A Case-Control Study

Introduction: Neuroendocrine tumors (NETs) are highly heterogeneous, serum chromogranin A (CgA) has a 60-100% of sensitivity and 68-100% of specificity with a cutoff value of 108 ng/mL as a marker for diagnosis of NETs.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Munoz Medel M

Authors: Munoz-Medel M, Cordova Delgado M, Pinto M, Bravo M, Retamal I,

Keywords: Neuroendocrine, Chromogranin A, Biomarker,

#2772 Vitamin Supplementation and a Personalized Diet in Patients with Neuroendocrine Tumors: The DIVIT Study

Introduction: Patients with neuroendocrine tumors (NETs) are at risk for vitamin deficiencies and poor nutritional status due to excessive serotonin production, diarrhea, previous gastrointestinal surgery, and/or treatment with somatostatin analogues (SSA). Little knowledge exists about vitamin deficiency and how patients should be supported for the deficiencies they develop during their long-lasting disease.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Stelwagen J

Authors: Stelwagen J, de Hosson L, Sijtema B, van Faassen M, Kema I,

Keywords: Vitamins, nutritional support, supplementation, vitamin deficiency, single-arm intervention,

#2765 Role of Biomarkers in Disease Progression of NET

Introduction: Due to the non specific features of neuroendocrine tumors and lack of diagnostic biomarkers, the diagnosis is usually delayed and almost half of patients presenting with distant metastases

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Fatima A

Authors: Fatima A, Zaidi S,

Keywords: biomarker, CgB, CART, CgA,